Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.16, Iss.7, 2007-07, pp. : 1111-1120

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Management of cutaneous T-cell lymphoma

By Duhovic Chris Child Fiona Wain E Mary

Clinical Medicine, Vol. 12, Iss. 2, 2012-04 ,pp. : 160-164

Royal College Of Physicians

Access to resources Recommend Favorite

Disposition of Vorinostat, A Novel Histone Deacetylase Inhibitor and Anticancer Agent, in Preclinical Species

Drug Metabolism Letters, Vol. 1, Iss. 2, 2007-04 ,pp. : 153-161

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacological Characterization of Histone Deacetylase Inhibitor and Tumor Cell-Growth Inhibition Properties of New Benzofuranone Compounds

Current Cancer Drug Targets, Vol. 11, Iss. 8, 2011-01 ,pp. : 919-928

Bentham Science Publishers

Access to resources Recommend Favorite

Efalizumab: Progression of cutaneous T-cell lymphoma: case report

Reactions Weekly, Vol. 1, Iss. 1238, 2009-01 ,pp. : 11-12

Adis International

Access to resources Recommend Favorite

Denileukin diftitox improves QOL in cutaneous T-cell lymphoma

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 360, 2002-01 ,pp. : 10-11

Adis International

Access to resources Recommend Favorite